These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10506629)

  • 1. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
    J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
    Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
    Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
    Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
    Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
    Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
    Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
    Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
    Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
    Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan, cisplatin, and radiation in esophageal cancer.
    Ilson DH; Minsky B; Kelsen D
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
    Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
    Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer.
    Kim M; Keam B; Kim TM; Kim HG; Kim JS; Lee SS; Shin SH; Kim MK; Park KU; Kim DW; Yun HJ; Lee JS; Heo DS
    Cancer Res Treat; 2017 Apr; 49(2):416-422. PubMed ID: 27488873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
    Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters JS; Hill ME; Norman AR
    Ann Oncol; 2004 Jan; 15(1):64-9. PubMed ID: 14679122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
    Taïeb J; Artru P; Baujat B; Mabro M; Carola E; Maindrault F; Tournigand C; Krulik M; Louvet C; de Gramont A
    Eur J Cancer; 2002 Mar; 38(5):661-6. PubMed ID: 11916548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
    Janjigian YY; Ku GY; Campbell JC; Shah MA; Capanu M; Kelsen DP; Ilson DH
    Am J Clin Oncol; 2014 Apr; 37(2):126-30. PubMed ID: 23211227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.